Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Swiss Cancer Institute
MingSight Pharmaceuticals, Inc
University of Pennsylvania
University of Washington
Barbara Ann Karmanos Cancer Institute
Exelixis
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Radboud University Medical Center